Executive readout · one minute
What the filings say
- 8-K earnings release · filed Oct 29, 2026
- Kymera Therapeutics reported third-quarter 2026 results: a $132.0 million net loss and $1.6 billion in cash, cash equivalents and investments as of September 30, 2026. KT-579 Phase 1 results were positive, while KT-621 BROADEN2 topline data are planned by year-end 2026.
- 10-Q report · filed Oct 29, 2026
- Kymera Therapeutics posted a $132.0 million net loss for the quarter ended September 30, 2026 as research and development expenses rose to $128.5 million from $74.1 million. Cash, cash equivalents and marketable securities were $1,646 million, expected to fund operations into 2029.
The audio replay and transcript follow the call.